Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients
Clinical trial NCT02625337 · UNKNOWN
Trial details
- NCT number
- NCT02625337
- Sponsor
- The Netherlands Cancer Institute
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-01-01
- Primary completion
- 2018-06-01
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.